Auxilium Pharmaceuticals Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the first cohort of patients has been dosed in its phase Ib trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of edematous fibrosclerotic panniculopathy, commonly known as cellulite. Cellulite has been reported to occur in 85-98% of post-pubertal females and rarely in men. The condition is prevalent in women of all races. (1,3)
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.